Early Phase 1
N=125
mHealth to Help Pregnant and Postpartum Women in Recovery for Opioid Use Disorder
Opioid Use Disorders
Bottom Line
View on ClinicalTrials.gov: NCT06701123 ↗Enrolled (actual)
125
Serious AEs
0.0%
Results posted
Apr 2026
Primary outcome: Primary: Cravings — 11.90; 8.94; 11.10; 8.21 score on a scale (total score, 0 to 30) — p=0.12
Study Design & Population
- Study type
- Interventional
- Phase
- Early Phase 1
- Interventions
- uMAT-R mobile app with coaching component (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Washington University School of Medicine
- Primary completion
- Oct 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Cravings |
11.90; 8.94; 11.10; 8.21 | 0.12 |
| PRIMARY MOUD Attitudes |
3.52; 3.35; 3.11; 2.92 | 0.51 |
Summary
The opioid epidemic has resulted in widespread detrimental consequences among vulnerable populations in Missouri, especially among pregnant and postpartum women (PPW) with opioid use disorder (OUD). Perinatal use of medication-assisted treatment (MAT) within a comprehensive treatment plan is the current standard of care, however PPW struggling with OUD may underestimate or misjudge its benefits. At the same time, emerging findings signal that mobile health (mHealth) technologies have the potential to support healthier behaviors among individuals with OUD. In this project, we will test the utility of a theoretically-based digital therapeutics tool (uMAT-R) to encourage MAT adherence and treatment retention while considering the unique needs of PPW. We will conduct a pilot randomized controlled trial (RCT) among adult PPW with OUD. This RCT is designed to test the feasibility, acceptability, and preliminary efficacy of uMAT-R mobile app versus a control group (who receive treatment-as-usual) regarding participants' treatment adherence, sobriety, and improved MAT attitudes, norms, and perceived control. Recruitment for all Aims will occur at a clinic in St. Louis, Missouri that provides perinatal medication-assisted treatment (MAT) and high-risk maternity care to PPW struggling with OUD. Clinically meaningful effect size and attrition estimates will aid in the planning of a larger RCT in which we will test uMAT-R on a larger scale and expand our recruitment to other clinics across Missouri and other states. In addition, local providers who work with pregnant and postpartum people with substance use disorder and/or at a recovery community center will be recruited to provide their feedback. This novel technology could be an invaluable tool to assist physicians in the treatment of OUD among PPW.
Eligibility Criteria
Pregnant and Postpartum Participants:
Inclusion Criteria
- Pregnant or up to 3 years postpartum
- Receiving treatment consenting treatment facility and/or referred from other participants or community partners
- Adult (≥18 years of age)
- U.S. resident
- OUD or history of opioid misuse
- Fluent in English
- Own a smartphone with an iOS or Android operating system
Exclusion Criteria
- Currently incarcerated
Providers Inclusion Criteria:
- Works with pregnant and postpartum people with opioid use disorder and/or at a recovery community center (e.g. a staff person, counselor, social worker, psychiatrist, nurse).
- Adult (≥18 years of age)
- Fluent in English
- Own a smartphone with an iOS or Android operating system
Data sourced from ClinicalTrials.gov (NCT06701123). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.